Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
2023
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources.
A Markov model was used to estimate quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Two treatment approaches were compared: one targeting systolic blood pressure at 110-130 mm Hg and the other at 130-150 mm Hg. The analysis used a healthcare payer's perspective.
The results showed that intensive blood pressure control produced fewer cardiovascular events and was associated with incremental cost-effectiveness ratios that were well below the cost per QALY gained, reflecting typical willingness-to-pay thresholds in each of the countries. These general results were consistent across sensitivity and subgroup analyses.
Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
Source:
Liao C, Toh HS, Sun L et al. Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients with Hypertension. JAMA Network Open 2023; 6 (2): e230708. https://doi.org/10.1001%2Fjamanetworkopen.2023.0708